phrykt

CalciMedica, Inc. (CALC): who owns it and who trades it

As of Nov 16, 2026, CALC insiders reported 1 purchase worth $199K in the last 12 months. The largest buyer was Fred A Middleton (Director), with $199K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling CalciMedica

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, CALC insiders reported $199K of open-market purchases and $0 of sales.

Purchases, 12 months
$199K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 25, 2026
Filed Jun 29, 2026

Purchases and sales by month

$199K$199KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 25, 2026Fred A MiddletonDirectorPurchase248,972$0.80$199KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Fred A MiddletonDirector, 10% owner$199K–Jun 25, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CALC short interest

Low short interest. 0.5% of CALC shares are sold short: about 1 share in 199. Over the last 12 reports the number of shares short went up 26%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 171,388 CALC shares were sold short, 0.5% of the shares outstanding, up 178.0% from the report before. At the average daily volume of 96,501 shares, buying them all back would take about 1.8 trading days (days to cover).

Shares short, % of all shares

0.50%May 15Oct 3012.0%

Days to cover

1.8May 15Oct 302.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026171,3880.50%+178%96,5011.8
Oct 15, 202661,6410.18%-29%70,4591.0
Sep 30, 202686,4330.25%-23%57,7311.5
Sep 15, 2026111,7030.33%-13%98,5691.1
Aug 31, 2026127,6840.37%-60%99,8621.3
Aug 14, 2026323,2410.95%-36%320,7041.0
Jul 31, 2026503,0703.20%-48%277,4301.8
Jul 15, 2026960,7316.10%-42%406,8812.4
Jun 30, 20261.65M10.49%+498%6.19M1.0
Jun 15, 2026276,3261.76%+91%459,2711.0
May 29, 2026144,3560.92%+6%152,3751.0
May 15, 2026136,4110.87%-19%138,6411.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

CalciMedica company events

CalciMedica filed 16 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 16, 2026LeadershipStephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc., provided notice of his resignation, to be effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30… Filing
  3. Sep 30, 2026AnnouncementCalciMedica, Inc. filed a prospectus supplement related to the sale of the Company’s common stock, par value $0.0001 per share with the Securities and Exchange Commission pursuant to which the Company may offer and sell Common Stock having an aggregate offering price of up to $25 million from time… Filing
  4. Sep 16, 2026AnnouncementAs previously disclosed, on March 16, 2026, CalciMedica, Inc. received notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC that the Company was not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had… Filing
  5. Sep 2, 2026AnnouncementMarket Value of Listed Securities As previously disclosed, on March 13, 2026, CalciMedica, Inc. received notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC that the Company was not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of… Filing
  6. Aug 27, 2026RulesChanged its bylaws or articles. Filing
  7. Aug 20, 2026LeadershipCalciMedica, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  8. Aug 11, 2026ResultsReleased financial results. Filing
  9. Jul 7, 2026LeadershipThe board of directors of CalciMedica, Inc., a Delaware corporation, upon recommendation of the Nominating and Corporate Governance Committee of the Board, increased the size of the Board from seven directors to eight directors. Filing
  10. Jun 24, 2026AgreementCalciMedica, Inc. entered into a securities purchase agreement with certain new and existing institutional and accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement of an aggregate of 18,673,429 units, each Unit comprised of (i) (A)… Filing
  11. Jun 24, 2026AgreementCalciMedica, Inc. entered into the First Amendment to Loan Documents to amend that certain Loan and Security Agreement and that certain Supplement to the Loan and Security Agreement each dated as of February 28, 2025 (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P.… Filing
  12. May 12, 2026ResultsReleased financial results. Filing
  13. Mar 18, 2026ListingCalciMedica, Inc. received notice from The Nasdaq Stock Market LLC that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities for the Company’s common stock had been below the minimum MVLS Requirement of $35 million for the last 30… Filing
  14. Mar 3, 2026ResultsReleased financial results. Filing
  15. Jan 28, 2026AnnouncementCalciMedica, Inc. announced the discontinuation of its Phase 2 KOURAGE clinical trial following a recommendation from the trial’s Independent Data Monitoring Committee. Filing
  16. Jan 28, 2026AnnouncementThe Company announced the Trial Discontinuation. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

CalciMedica financials

Famous investors that hold CALC

1 of the 50 well-known investors we track reported holding CALC in their latest 13F filing. The largest position is Jim Simons's, worth $77.7K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202647,980$77.7K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named CALC in the last 120 days.

FiledHolderFormStake
Nov 16, 2026StemPoint Capital LP13G9.9%
Nov 16, 2026StemPoint Capital LP13G9.9%
Nov 16, 2026Armistice Capital, LLC13G/A5.7%
Nov 16, 2026CVI Investments, Inc.13G/A4.9%
Nov 16, 2026Armistice Capital, LLC13G/A5.7%
Nov 16, 2026Stonepine Capital Management, LLC13G/A8.1%
Nov 16, 2026CVI Investments, Inc.13G/A4.9%
Nov 16, 2026Stonepine Capital Management, LLC13G/A8.1%

Questions about CalciMedica, Inc. (CALC) stock

Are CALC insiders buying or selling?

In the last 12 months, CALC insiders reported 1 open-market purchase worth $199K and no sales. The latest trade was on Jun 25, 2026. See every trade.

What is the short interest in CALC?

As of Oct 30, 2026, 171,388 CALC shares were sold short, 0.5% of the shares outstanding, up 178.0% from the report before. At the average daily volume of 96,501 shares, buying them all back would take about 1.8 trading days (days to cover). See the history.

Which famous investors hold CALC?

1 of the 50 well-known investors we track reported CALC in their latest 13F filing, including Jim Simons. The largest position is worth $77.7K. See all holders.

Executive pay

CalciMedica's chief executive was paid a total of $895K for the year ended Dec 31, 2025, down 46% from $1.7M the year before. In the last 12 months, CalciMedica's executives and directors bought $199K of stock on the open market and sold none.

Chief executive, total pay$895KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$733KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.